Apolipoprotein C-II Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Apolipoprotein C-II Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>APOC2</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Apolipoprotein C-II</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~8.9 kDa (79 amino acids)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>ApoC-II, LPL activator</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P02655</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Liver (primary), intestine (minor)</td>
</tr>
<tr>
<td class="label">Hormone</td>
<td>Effect on APOC2</td>
</tr>
<tr>
<td class="label">Insulin</td>
<td>Suppresses expression</td>
</tr>
<tr>
<td class="label">Estrogen</td>
<td>Increases expression</td>
</tr>
<tr>
<td class="label">Glucocorticoids</td>
<td>Increases expression</td>
</tr>
<tr>
<td class="label">Thyroid Hormone</td>
<td>Variable effects</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Recombinant APOC2</td>
<td>LPL cofactor replacement</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-APOC2</td>
</tr>
<tr>
<td class="label">LPL Gene Therapy</td>
<td>Direct LPL delivery</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Fibrates</td>
<td>PPAR-α activation<
...Apolipoprotein C-II Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Apolipoprotein C-II Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>APOC2</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Apolipoprotein C-II</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~8.9 kDa (79 amino acids)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>ApoC-II, LPL activator</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P02655</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Liver (primary), intestine (minor)</td>
</tr>
<tr>
<td class="label">Hormone</td>
<td>Effect on APOC2</td>
</tr>
<tr>
<td class="label">Insulin</td>
<td>Suppresses expression</td>
</tr>
<tr>
<td class="label">Estrogen</td>
<td>Increases expression</td>
</tr>
<tr>
<td class="label">Glucocorticoids</td>
<td>Increases expression</td>
</tr>
<tr>
<td class="label">Thyroid Hormone</td>
<td>Variable effects</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Recombinant APOC2</td>
<td>LPL cofactor replacement</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-APOC2</td>
</tr>
<tr>
<td class="label">LPL Gene Therapy</td>
<td>Direct LPL delivery</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Fibrates</td>
<td>PPAR-α activation</td>
</tr>
<tr>
<td class="label">Omega-3 fatty acids</td>
<td>LPL enhancement</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>APOC2 replacement</td>
</tr>
</table>
Introduction
Apolipoprotein C Ii Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Apolipoprotein C-II (APOC2) is a 79-amino acid protein component of very-low-density lipoproteins (VLDL) and high-density lipoproteins (HDL). It serves as an essential cofactor for lipoprotein lipase (LPL), the enzyme responsible for hydrolyzing triglycerides in circulating lipoproteins. APOC2 is primarily synthesized in the liver and secreted into the plasma, where it associates with triglyceride-rich lipoprotein particles. The protein plays a critical role in maintaining lipid homeostasis, and its dysfunction can lead to severe metabolic disorders. [@berbee2006]
Structure
APOC2 is a small apolipoprotein with several key structural features:
- Amphipathic Alpha-Helical Domains: Two major helical regions for lipid binding
- N-terminal Region: Critical for LPL interaction and activation
- C-terminal Region: Mediates lipoprotein particle association
- Disulfide Bonds: None (lacks cysteine residues)
- Glycosylation: Not significantly glycosylated
The amphipathic helices allow APOC2 to associate with the phospholipid surface of lipoproteins while exposing the LPL-binding region to the aqueous phase.
Molecular Function
Lipoprotein Lipase Activation
APOC2 is the essential cofactor for LPL-mediated triglyceride hydrolysis:
- Binds to LPL through specific N-terminal residues
- Induces conformational change in LPL enabling catalysis
- Facilitates anchoring of LPL to the lipoprotein surface
- One molecule of APOC2 can activate multiple LPL enzymes
The LPL-APOC2 complex hydrolyzes triglycerides in:
- Chylomicrons: Dietary triglycerides from intestine
- VLDL: Endogenous triglycerides from liver
- IDL: Intermediate density lipoproteins
Lipoprotein Particle Dynamics
APOC2 exchanges between different lipoprotein classes:
- Transfers from HDL to triglyceride-rich lipoproteins
- Can be displaced by other apolipoproteins (APOC3, APOE)
- Remodeling of lipoprotein particles during lipolysis
Expression and Regulation
Tissue Distribution
- Hepatocytes: Primary site of synthesis
- Intestinal Enterocytes: Minor contribution
- Macrophages: Inflammatory conditions may induce expression
Hormonal Regulation
- Fasting: Decreased hepatic APOC2 expression
- Feeding: Increased expression to promote triglyceride clearance
- High-carbohydrate diet: Upregulation
Disease Implications
Hypertriglyceridemia
- APOC2 Deficiency: Rare autosomal recessive disorder causing severe hypertriglyceridemia (type I hyperlipoproteinemia)
- Chylomicronemia syndrome
- Recurrent pancreatitis
- Eruptive xanthomas
Alzheimer's Disease
- Altered APOC2 levels in AD patients
- Potential role in brain lipid homeostasis
- May affect [amyloid-beta](/proteins/amyloid-beta) metabolism
- Interaction with [APOE](/proteins/apoe-protein) isoforms
Cardiovascular Disease
- Triglyceride-rich lipoproteins are independent cardiovascular risk factor
- APOC2 modulates atherogenic potential
- May affect postprandial lipemia
- Elevated APOC2 associated with insulin resistance
- Component of dyslipidemia (high TG, low HDL)
- Predictor of type 2 diabetes
Therapeutic Targeting
Current Approaches
Emerging Strategies
- Antisense Oligonucleotides: Target APOC2 to lower triglycerides
- Small Molecule LPL Activators: Bypass APOC2 requirement
- Monoclonal Antibodies: Neutralize APOC2 in severe cases
Animal Models
- APOC2 Knockout Mice: Mild hypertriglyceridemia (species differences in LPL regulation)
- Transgenic Overexpression: Severe hypolipidemia
- AAV-mediated Expression: Used for gene therapy studies
Research Directions
- Understanding APOC2 transport across the [blood-brain barrier](/entities/blood-brain-barrier)
- Brain-specific functions in lipid metabolism
- Biomarker potential: APOC2 as metabolic marker
- Development of brain-penetrant LPL activators
Background
The study of Apolipoprotein C Ii Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- APOC2 Gene
- [APOC3 Protein](/proteins/apoc3-protein)
- [Lipid Metabolism](/mechanisms/lipid-metabolism-neurodegeneration)
- Hypertriglyceridemia
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- Cardiovascular Disease and Dementia
External Links
- [APOC2 Protein - NCBI](https://www.ncbi.nlm.nih.gov/protein/NP_000001)
- [UniProt: P02655](https://www.uniprot.org/uniprot/P02655)
- [APOC2 - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=APOC2)
Molecular Mechanisms
Lipoprotein Lipase Activation
Apolipoprotein C-II (apoC-II) is an essential cofactor for lipoprotein lipase (LPL):
- Activates LPL to hydrolyze triglycerides in chylomicrons and VLDL
- Structural requirement for LPL dimerization
- Accelerates triglyceride clearance from plasma
- Regulates postprandial lipid levels
- Mediates chylomicron catabolism
Lipid Transport
ApoC-II participates in lipid metabolism:
- Component of chylomicrons and VLDL
- Exchanges between lipoprotein particles
- Modulates lipoprotein particle size
- Influences remnant clearance
Disease Associations
Hypertriglyceridemia
- APOC2 mutations cause familial hypertriglyceridemia
- Loss of LPL activation function
- Severe elevation of plasma triglycerides
- Risk of pancreatitis
- Treatment: fibrates, omega-3 fatty acids
Cardiovascular Disease
- Elevated apoC-II associated with CVD risk
- Triglyceride-rich lipoprotein remnants
- Atherosclerosis promotion
- Biomarker potential for cardiovascular risk
Alzheimer's Disease
- ApoC-II in brain lipid metabolism
- Potential role in neuronal lipid homeostasis
- May influence neurodegeneration
- Research ongoing
Therapeutic Approaches
Research Directions
- Understanding APOC2 gene regulation
- Developing apoC-II mimetic peptides
- ApoC-II and cognitive function
- Biomarker studies
References